A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Treating Pain Experienced by Subjects With Confirmed Small Fibre Neuropathy That is Idiopathic or Associated With Diabetes Mellitus
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Vixotrigine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Biogen
- 24 Jan 2018 Planned End Date changed from 1 Jul 2019 to 27 Aug 2020.
- 24 Jan 2018 Planned primary completion date changed from 1 Jul 2019 to 27 Aug 2020.
- 24 Jan 2018 Planned initiation date changed from 1 Mar 2018 to 10 May 2018.